Levobupivacaine Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine is used in regional anesthesia to provide targeted nerve blockade for various surgical and obstetric procedures.

• Surgical anesthesia: provides dense sensory and motor block for operative procedures.
• Post‑operative analgesia: extends pain relief after surgery, reducing opioid requirement.
• Labor analgesia: offers effective pain control during childbirth while preserving maternal consciousness.
• Peripheral nerve block: enables localized anesthesia for limb surgeries and diagnostic procedures.

• Levobupivacaine exerts its effect by reversibly binding to the intracellular portion of voltage‑gated sodium channels in neuronal membranes. This blockade prevents the influx of sodium ions during depolarization, thereby inhibiting the initiation and propagation of nerve impulses. The resulting interruption of signal transmission produces loss of sensation and motor function in the targeted area, allowing surgical or analgesic procedures to be performed without pain.

Levobupivacaine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypotension: transient drop in blood pressure that may cause light‑headedness.
• Bradycardia: slowed heart rate, particularly observed with high spinal or epidural doses.
• Dizziness or light‑headedness: sensation of unsteadiness or faintness after injection.
• Nausea or vomiting: gastrointestinal upset that can occur shortly after administration.
• Metallic taste: brief metallic sensation in the mouth following injection.
• Injection site pain or erythema: local discomfort, redness, or swelling at the injection site.

Serious or Rare Side Effects

• Cardiac arrhythmia: abnormal heart rhythms, potentially life‑threatening, especially with intravascular injection.
• Seizures: central nervous system excitation due to excessive plasma concentrations.
• Respiratory depression: reduced breathing effort that may require ventilatory support.
• Prolonged motor block: extended loss of muscle function beyond the expected duration of anesthesia.
• Allergic reaction: urticaria, angioedema, or anaphylaxis requiring immediate medical attention.
• Methemoglobinemia: rare blood disorder causing reduced oxygen delivery to tissues.

When using Levobupivacaine, clinicians should observe several safety measures to minimize risks.

• Patient monitoring: continuous cardiovascular and respiratory monitoring during and after administration.
• Dose adjustment: reduce dose in patients with hepatic impairment due to slower metabolism.
• Avoid in hypersensitivity: do not use in individuals with known allergy to amide‑type local anesthetics.
• Caution in cardiac disease: use carefully in patients with pre‑existing cardiac conduction abnormalities.
• Avoid concurrent local anesthetics: do not combine with other amide local anesthetics to prevent additive toxicity.
• Store at ambient temperature: keep in original container, protect from light and moisture, and do not freeze.

Levobupivacaine can interact with other drugs, affecting its safety profile.

Major Interactions (Avoid)

• Other local anesthetics: concurrent use may cause additive systemic toxicity.
• Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiac conduction disturbances.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma levels of levobupivacaine.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance bradycardic effects.
• Diuretics: can potentiate hypotensive response.
• General anesthetics (e.g., propofol, volatile agents): may increase depth of neural block.